Premium
Intestinal transit of an orally administered streptomycin–rifampicin‐resistant variant of Bifidobacterium longum SBT2928: its long‐term survival and effect on the intestinal microflora and metabolism
Author(s) -
Fujiwara S.,
Seto Y.,
Kimura A.,
Hashiba H.
Publication year - 2001
Publication title -
journal of applied microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.889
H-Index - 156
eISSN - 1365-2672
pISSN - 1364-5072
DOI - 10.1046/j.1365-2672.2001.01205.x
Subject(s) - bifidobacterium longum , streptomycin , rifampicin , microbiology and biotechnology , bifidobacterium , antibiotics , biology , gastrointestinal transit , pharmacology , medicine , bacteria , genetics , lactobacillus
S. FUJIWARA, Y. SETO, A. KIMURA AND H. HASHIBA. 2001 . Aims: The objectives of this study are to investigate the fate of a streptomycin–rifampicin‐resistant variant of Bifidobacterium longum SBT2928 (BL2928SR) and the influence of its oral administration on the composition and metabolism of the intestinal microflora. Methods and Results: Intestinal passage of BL2928SR was monitored by a combination of selection with antibiotics and identification by a randomly amplified polymorphic DNA (RAPD)–PCR method. Intestinal microflora was analysed by the method developed by Mitsuoka et al. (1965, 1974). Long‐term survival of orally administered BL2928SR in the human intestine was confirmed. BL2928SR ingestion specifically lowered faecal populations of Enterobacteriaceae and clostridia, including lecithinase‐positive Clostridium spp. Conclusions: BL2928SR and its parent strain, BL2928, are considered to be appropriate candidates for probiotics. Significance and Impact of the Study: It is clarified that BL2928SR has the ability for long‐term survival in the human gastrointestinal tract, and alters the composition and metabolism of the intestinal microflora.